Hepatitis B Virus (HBV) Infection and Vaccine
A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Molecular Microbiology and Immunology".
Deadline for manuscript submissions: 15 September 2024 | Viewed by 678
Special Issue Editor
Special Issue Information
Dear Colleagues,
According to The Institut Pasteur data, hepatitis B is one of the most prevalent human diseases. It is estimated that two billion people have been infected by the virus. Chronic infection with hepatitis B virus (HBV) develops in millions of patients every year, despite the availability of effective prophylactic vaccines that can prevent hepatitis B. Chronic carriers have a high risk of dying from cirrhosis or liver cancer. These diseases cause about 887,000 deaths annually. The existing vaccines have proven to be highly effective in preventing HBV infection, but ongoing research aims to improve their efficacy, duration of protection, and accessibility. These vaccines are less effective in certain groups of people such as aged and obese people or are ineffective in chronic HBV carriers.
Therefore, the Special Issue “Hepatitis B virus infection and vaccine” aims to provide a collection of articles that highlight recent advancements in the field of hepatitis B. As the Guest Editor of this Special Issue, I invite you to submit research articles, review articles, and short communications related to Hepatitis B infection as well as to prophylactic and therapeutic vaccine development against this virus.
Dr. Irina Sominskaya
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatitis B
- chronic hepatitis B
- HB-based vaccine
- efficiency
- safety
